Dimensional Fund Advisors LP Acquires 85,305 Shares of ImmunityBio, Inc. $IBRX

Dimensional Fund Advisors LP lifted its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 345.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 110,009 shares of the company’s stock after purchasing an additional 85,305 shares during the period. Dimensional Fund Advisors LP’s holdings in ImmunityBio were worth $844,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IBRX. Vanguard Group Inc. lifted its position in ImmunityBio by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after buying an additional 5,122,052 shares in the last quarter. State Street Corp increased its position in ImmunityBio by 45.4% in the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after acquiring an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of ImmunityBio by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after acquiring an additional 1,030,113 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of ImmunityBio by 439.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after acquiring an additional 5,012,001 shares during the last quarter. Finally, Woodline Partners LP lifted its position in shares of ImmunityBio by 53.7% during the third quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock worth $13,032,000 after purchasing an additional 1,851,854 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $7.57 on Friday. ImmunityBio, Inc. has a 52 week low of $1.95 and a 52 week high of $12.43. The stock’s 50 day moving average price is $7.70 and its two-hundred day moving average price is $7.69. The stock has a market capitalization of $8.02 billion, a price-to-earnings ratio of -7.80 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. On average, equities research analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a report on Friday, July 10th. BTIG Research reaffirmed a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research report on Tuesday, June 2nd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.20.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 159,478 shares of ImmunityBio stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total value of $1,438,491.56. Following the sale, the director directly owned 35,064 shares in the company, valued at approximately $316,277.28. The trade was a 81.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $7.88, for a total transaction of $197,000.00. Following the sale, the director directly owned 2,802,788 shares in the company, valued at $22,085,969.44. This trade represents a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 435,443 shares of company stock valued at $3,918,819. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.